RE: RNS Commercial Update24 Mar 2025 11:20
Belgrano - funding needs will partly hinge on the success (or otherwise) of Opti's bigger sales partners (Morepen, Nouri etc). There's been recent mention of several new US ones coming on stream too.
If these continue to grow, Opti should eventually be able to grow organically from cashflow. But I suspect we're some way off that still. Of course, Sweetbiotix could also be a game changer, though supply start up costs are likely to be substantial.
As you said though, the noises from SOH suggest further sell downs of SBTX & PBX - at least in the short term. This from their 18th March 2025 RNS:
"We are pleased to see an increase in the value of company's shareholding in both Probiotix Health plc and SkinBiotherapeutics and see considerable growth potential in both these assets which can potentially be disposed of to pay shareholders an ad hoc dividend or sold down to reduce the need to fundraise in a volatile market."